Treats onychomycosis of the toenail or fingernail due to dermatophytes (tinea unguium). ANDA 78297, held by Aurobindo Pharma. Terbinafine Hydrochloride.
As of Nov 22, 2026, ANDA 78297 (Terbinafine Hydrochloride), held by Aurobindo Pharma, was first approved by FDA on Jul 2, 2007, with 10 approved supplements and 0 published complete response letters.
Terbinafine tablets are indicated for the treatment of onychomycosis of the toenail or fingernail due to dermatophytes (tinea unguium). Prior to initiating treatment, appropriate nail specimens for laboratory testing [potassium hydroxide (KOH) preparation, fungal culture, or nail biopsy] should be obtained to confirm the diagnosis of onychomycosis.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 2, 2007 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Terbinafine HydrochlorideEQ 250MG BASE · tablet;oral | Terbinafine Hydrochloride | Rx |
| Dec 3, 2019 | Supplement 20Labeling · Standard review | Approved | None posted |
| Dec 3, 2019 | Supplement 18Labeling · Standard review | Approved | None posted |
| Dec 3, 2019 | Supplement 17Labeling · Standard review | Approved | None posted |
| Dec 3, 2019 | Supplement 16Labeling · Standard review | Approved | None posted |
| Aug 25, 2015 | Supplement 13Labeling · Standard review | Approved | None posted |
| Aug 25, 2015 | Supplement 12Labeling · Standard review | Approved | None posted |
| Feb 5, 2013 | Supplement 10Labeling · Standard review | Approved | None posted |
| Sep 21, 2011 | Supplement 8Labeling | Approved | None posted |
| Jul 14, 2008 | Supplement 2Labeling | Approved | None posted |
| Apr 4, 2008 | Supplement 1Manufacturing | Approved | None posted |
| Jul 2, 2007 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters